Neurons give metastatic cells a push ..read more

TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma ..read more

Engineered model of heart tissue repair for exploring fibrotic processes and therapeutic interventions Engineered human models of hearts are needed to study pathology and repair. Here, the authors develop a model which replicates the phased remodelling process. The model is then used to study signalling pathway modulators for their therapeutic potential in a mini-repair model ..read more

Exploring the therapeutic potential of interleukin-6 receptor blockade in cardiovascular disease treatment through Mendelian randomization ..read more

in rat and human: insights from Ames test and S9 metabolic activation system ..read more

Label-free assessment of complement-dependent cytotoxicity of therapeutic antibodies via a whole-cell MALDI mass spectrometry bioassay ..read more

Uncovering naringin’s anticancer mechanisms in glioblastoma via molecular docking and network pharmacology approaches ..read more

MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity The anti-apoptotic protein MCL1 is a therapeutic target in cancer, but long-term MCL1 inhibition has been found to increase the risk of cardiotoxicity. We developed BRD-810 as a potent and selective MCL1 inhibitor that induces cancer cell death in vivo within a few hours. As BRD-810 was designed to be rapidly cleared, it targets cancer cells while minimizing the risk for cardiotoxicity ..read more

In the ongoing search for innovative treatments to combat refractory and relapsed cancer, new preclinical work in multiple myeloma shows that increasing binding avidity by targeting two antigens in one T cell-engaging trispecific antibody boosts anti-tumor activity and reduces the likelihood of tumor escape relative to current antibody-based therapies ..read more

“Clone-specific” antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers ..read more